Skip to main content
. 2016 Jul 22;7(33):53797–53807. doi: 10.18632/oncotarget.10777

Figure 4. Treatment of AD patients with memantine depletes CD45RO+ CD4+ T cells and suppresses T cell responsiveness.

Figure 4

A. Scheme for treatment of AD patients with memantine (Axura®). CD4+ T cells of AD patients undergoing memantine therapy were analyzed at time points Z1 (after initial diagnosis and before treatment), Z2 (after one week) and Z3 (after a total of 12 weeks of daily memantine treatment). B. The alloresponse of CD4+ T cells isolated from AD patients at Z1-Z3 was determined in MLRs by 3[H]-Thymidine incorporation; cpm values at Z1 were set as 100%. The graphs show the mean relative proliferation + SD of T cells from two groups of patients (group 1: 5-10 patients, group 2: 3 patients) responding to memantine treatment in a different manner, and for all (8-13) patients. C. PBMCs of memantine-treated patients were isolated at Z1-Z3 and analyzed for the content of CD45RO+ CD4+ T cells by flow cytometry. The left panel shows representative dot plots for CD4 expression and histograms for CD45RO levels on gated CD4+ T cells. The right graphs display the mean percentage + SD of CD4+ and CD45RO+ cells and the number of analyzed patients. The significance of data was determined with Student's t test with p*<0.05, p**<0.01, and p***<0.001.